JMP Securities lowered the firm’s price target on Prothena to $81 from $83 and keeps an Outperform rating on the shares. Prothena reported Q3 results ahead of consensus estimates and reiterated that the Phase 1 SAD/MAD results for amyloid-beta antibody, PRX012, remain on track to be announced by the end of the year, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRTA: